2024-02-14 14:04Commercial Performance of ZURZUVAE - ZURZUVAE, the first and only oral FDA-approved product for postpartum depression (PPD), recorded approximately 120 prescriptions written with 50 prescriptions delivered in December 2023[3][13] - The vast majority of initial prescriptions were covered by payers, with prescribing activity primarily driven by OBGYNs and psychiatrists[54] - Sage Therapeutics achieved a $75.0 million milestone payment from Biogen related to the first commercial sale of ZURZUVAE, which was received in January 2024[66][68] Financial Position and Results - The company reported a strong financial foundation with $0.8 billion in cash and marketable securities as of December 31, 2023[21][65] - Total revenue for the full year 2023 reached $86.5 million, compared to $7.7 million in 2022[21] - Net loss for the full year 2023 was $541.5 million, compared to a net loss of $532.8 million in 2022[21] - R&D expenses for the full year 2023 totaled $356.2 million, while SG&A expenses reached $274.5 million[21] Pipeline and Clinical Development - The company is advancing a differentiated pipeline targeting GABA and NMDA receptors, with multiple topline data readouts expected throughout 2024 for programs including SAGE-718 and SAGE-324[10][23][50] - The KINETIC2 study for SAGE-324 in essential tremor has completed enrollment, with further long-term safety evaluations ongoing[18][23]